Alzheimer's disease: From Molecular Basis to Therapy

Guest Editors:

**Dr. Greg T. Sutherland**
Charles Perkins Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia
g.sutherland@sydney.edu.au

**Prof. Dr. James Duce**
ALBORADA Drug Discovery Institute, University of Cambridge, Biomedical Campus, Hills Road, Cambridge CB2 0AH, UK
jad205@medschl.cam.ac.uk

Deadline for manuscript submissions:
**15 June 2022**

Message from the Guest Editors

Dear Colleagues,

Alzheimer’s disease (AD) manifests as a chronic deterioration in cognition, primarily in memory, resulting from neuronal loss in specific regions of the brain. Genetics and pathology suggest that beta-amyloid build-up is the key process in the disease, but efforts to pharmaceutically reduce beta-amyloid have not resulted in an expected slowing of cognitive decline. Assuming that amyloid reduction is insufficient for therapeutic relief, other targets are required, and this necessitates new knowledge on AD pathogenesis. In this respect, the increasingly complex multidimensional molecular (multi-omic) data being generated from clinical samples and AD models are both exciting and extremely challenging. The scope of this Special Issue is an exploration of the different approaches that research groups are using to narrow this knowledge gap around AD pathogenesis. Authors are invited to submit original research or review articles which address linking molecular studies to novel therapeutic avenues or preventive strategies for AD.
Message from the Editor-in-Chief

The International Journal of Molecular Sciences (IJMS, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. IJMS publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in IJMS and consider publishing your next paper with us.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed,PMC, MEDLINE, Embase, CAPIUS / SciFinder, and many other databases.

Journal Rank: JCR - Q1 (Biochemistry & Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)